A phase I study of a second-generation immunumodulatory oligonucleotide (HYB2055) in patients with advanced solid malignancies.

被引：0
|
作者：
Hwang, JJ
Martin, R
Fox-Sinclair, ES
Bahrani, A
Sullivan, T
Park, S
Agrawal, S
Burns, T
Waxdal, M
Marshall, JL
机构：
[1] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[2] Hybridon Inc, Cambridge, MA USA
[3] FAST Syst Inc, Gaithersburg, MD USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6230S / 6230S
页数：1
相关论文
共 50 条
  • [1] A phase I study of HYB2055 in patients (pts) with advanced solid malignancies
    Hwang, JJ
    Park, S
    Amin, A
    Martin, RR
    Sullivan, T
    Burns, T
    Agrawal, S
    Waxdal, MJ
    Malik, S
    Marshall, JL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 222S - 222S
  • [2] Preclinical antitumor evaluation of a second-generation immunomodulatory oligonucleotide (IMO), HYB2055, alone and in combination with taxotere and gemcitabine.
    Wang, H
    Huang, P
    Kandimalla, ER
    Yu, D
    Agrawal, S
    Zhang, RW
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6231S - 6231S
  • [3] Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors.
    Moore, DJ
    Hwang, J
    McGreivy, J
    Park, S
    Malik, S
    Martin, RR
    Sullivan, TM
    Agrawal, S
    Marshall, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 166S - 166S
  • [4] A phase 1 placebo-controlled study in volunteers of escalating doses of HYB2055, a second-generation immunomodulatory agent based on CpG DNA.
    Martin, R
    Sullivan, T
    Bhagat, L
    Kandimalla, E
    Wang, D
    Zhao, Q
    Burton, C
    Bryson, P
    Ng, T
    Binney, S
    Handy, L
    Agrawal, S
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6227S - 6227S
  • [5] Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies.
    Mittal, Kriti
    Koon, Henry B.
    Elson, Paul
    Triozzi, Pierre L.
    Dowlati, Afshin
    Borden, Ernest C.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.
    Cohen, E. E.
    Sharma, M.
    Janisch, L. A.
    Stadler, W. M.
    Kang, S. P.
    Fleming, G. F.
    Ratain, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A phase I study of reolysin given intravenously to patients with advanced malignancies.
    Vidal, L.
    Pandha, H.
    Spicer, J.
    Harrington, K. J.
    Allen, S.
    Leader, D.
    Coffey, M.
    Thompson, B.
    Kaye, S.
    De-Bono, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 136S - 136S
  • [8] A phase I combination study of irofulven (IROF) and gemcitabine (GEM) in patients (pts) with advanced solid malignancies.
    O'Bryant, CL
    Gore, L
    Long, M
    Gustafson, D
    Eppers, S
    Basche, M
    Rothenberg, M
    Weems, G
    Shah, A
    Herdrich, L
    Eckhardt, SG
    Berlin, J
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9119S - 9120S
  • [9] A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
    Owonikoko, Taofeek Kunle
    Harvey, R. Donald
    Kauh, John S.
    Lewis, Colleen Margaret
    Hossain, Mohammed S.
    Akintayo, Adebowale O.
    Merriewether, A. Rene
    Chen, Zhengjia
    Hawk, Natalyn Nicole
    Saba, Nabil F.
    Harris, Wayne
    Shin, Dong Moon
    El-Rayes, Bassel F.
    Huang, Chunzi
    Lonial, Sagar
    Lawson, David H.
    Khuri, Fadlo Raja
    Waller, Edmund K.
    Ramalingam, Suresh S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] A phase I Study of ecteinascidin 743(E) and capecitabine (C) in patients (pts) with advanced solid malignancies.
    Holden, SN
    Rivera, E
    Basche, M
    Gore, L
    Raj, SKS
    O'Bryant, CL
    Grolnic, S
    Hunt, J
    Brillhart, B
    Van de Velde, H
    Roberts, D
    Rodgers, J
    Eckhardt, SG
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6080S - 6080S
12345